QT Imaging Holdings (OTCQB: QTIH) has announced the appointment of Satrajit Misra, as Chief Commercial Officer (CCO).
Mr. Misra’s appointment underscores QT Imaging’s (QTI) commitment to innovation, clinical excellence, and commercial execution in delivering accessible, radiation-free, contrast-free, and compression-free breast imaging technologies for women worldwide.
In a statement, Dr. Raluca Dinu, CEO of QTI, commented, “We are thrilled to welcome Satrajit as our CCO as we advance commercialization and pivot toward a SaaS and biomarker-driven franchise. Satrajit’s deep domain experience in building and scaling state-of-the-art medical imaging franchises, his strong relationships among leading radiology and oncology thought leaders, and his proven success in driving growth and innovation across imaging and MedTech enterprise, will be instrumental as we accelerate adoption of our innovative diagnostic technologies.”
A seasoned executive with three decades of progressive leadership in radiology, oncology and molecular imaging, Mr. Misra is recognized for his expertise in scaling complex businesses, leading acquisitions and integrations, and forging high-impact alliances to expand into white-space markets. He comes to QTI from the company’s strategic partner, Canon Medical Systems USA (Canon USA), where he most recently served as Executive SVP, Chief Sales and Marketing Officer. Prior to first joining Canon USA in 2012, Mr. Misra was Philips’ Head of Business Development and Marketing, and before that, Siemens Healthcare’s Director of Business Management. Mr. Misra has a Bachelor of Science and a Bachelor of Technology in applied physics from the University of Calcutta in India, attended the School of Business and Economic Studies at the University of Leeds in the United Kingdom, and has a certificate in negotiation from Harvard Business School in the United States.
In this newly created c-suite role at QTI, Mr. Misra will drive commercial scale-up and clinical partnerships, positioning the company as a modality of choice for supplemental breast screening and biomarker-driven precision diagnostics.
“I’m excited to join QTI at this pivotal inflection point as we bring our transformative breast imaging technology to scale and redefine standards in early detection and precision diagnostics,” said Mr. Misra. “While I worked closely with Raluca and her team via the company’s ongoing strategic partnership with Cannon USA, it was captivating to watch the scale, scope and speed with which QTI had already begun to transform breast health management for the potential benefit of millions of patients. I look forward to working with the QTI team to develop and expand the product pipeline, accelerate growth, and enhance value for our shareholders.”
